AU2016328969B2 - Detecting and treating growth hormone deficiency - Google Patents

Detecting and treating growth hormone deficiency Download PDF

Info

Publication number
AU2016328969B2
AU2016328969B2 AU2016328969A AU2016328969A AU2016328969B2 AU 2016328969 B2 AU2016328969 B2 AU 2016328969B2 AU 2016328969 A AU2016328969 A AU 2016328969A AU 2016328969 A AU2016328969 A AU 2016328969A AU 2016328969 B2 AU2016328969 B2 AU 2016328969B2
Authority
AU
Australia
Prior art keywords
test
child
ghd
children
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016328969A
Other languages
English (en)
Other versions
AU2016328969A1 (en
Inventor
Michael THORNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of AU2016328969A1 publication Critical patent/AU2016328969A1/en
Assigned to Ammonett Pharma LLC reassignment Ammonett Pharma LLC Amend patent request/document other than specification (104) Assignors: AMMONETT PHARM LLC
Priority to AU2020233715A priority Critical patent/AU2020233715B2/en
Application granted granted Critical
Publication of AU2016328969B2 publication Critical patent/AU2016328969B2/en
Priority to AU2021254600A priority patent/AU2021254600B2/en
Assigned to LUMOS PHARMA, INC. reassignment LUMOS PHARMA, INC. Request for Assignment Assignors: Ammonett Pharma LLC
Priority to AU2024201658A priority patent/AU2024201658B2/en
Priority to AU2025237934A priority patent/AU2025237934A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/61Growth hormones [GH] (Somatotropin)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2016328969A 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency Active AU2016328969B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2020233715A AU2020233715B2 (en) 2015-09-21 2020-09-17 Detecting and treating growth hormone deficiency
AU2021254600A AU2021254600B2 (en) 2015-09-21 2021-10-21 Detecting and treating growth hormone deficiency
AU2024201658A AU2024201658B2 (en) 2015-09-21 2024-03-14 Detecting and treating growth hormone deficiency
AU2025237934A AU2025237934A1 (en) 2015-09-21 2025-09-24 Detecting and treating growth hormone deficiency

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US62/221,191 2015-09-21
US201662289221P 2016-01-30 2016-01-30
US62/289,221 2016-01-30
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020233715A Division AU2020233715B2 (en) 2015-09-21 2020-09-17 Detecting and treating growth hormone deficiency

Publications (2)

Publication Number Publication Date
AU2016328969A1 AU2016328969A1 (en) 2018-04-26
AU2016328969B2 true AU2016328969B2 (en) 2020-10-08

Family

ID=58276481

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2016328969A Active AU2016328969B2 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency
AU2020233715A Active AU2020233715B2 (en) 2015-09-21 2020-09-17 Detecting and treating growth hormone deficiency
AU2021254600A Active AU2021254600B2 (en) 2015-09-21 2021-10-21 Detecting and treating growth hormone deficiency
AU2024201658A Active AU2024201658B2 (en) 2015-09-21 2024-03-14 Detecting and treating growth hormone deficiency
AU2025237934A Pending AU2025237934A1 (en) 2015-09-21 2025-09-24 Detecting and treating growth hormone deficiency

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2020233715A Active AU2020233715B2 (en) 2015-09-21 2020-09-17 Detecting and treating growth hormone deficiency
AU2021254600A Active AU2021254600B2 (en) 2015-09-21 2021-10-21 Detecting and treating growth hormone deficiency
AU2024201658A Active AU2024201658B2 (en) 2015-09-21 2024-03-14 Detecting and treating growth hormone deficiency
AU2025237934A Pending AU2025237934A1 (en) 2015-09-21 2025-09-24 Detecting and treating growth hormone deficiency

Country Status (23)

Country Link
US (4) US9763919B2 (enExample)
EP (3) EP4296679A3 (enExample)
JP (5) JP6816149B2 (enExample)
KR (4) KR20230116961A (enExample)
CN (2) CN108348501A (enExample)
AU (5) AU2016328969B2 (enExample)
CA (1) CA2998523C (enExample)
CY (1) CY1125183T1 (enExample)
DK (2) DK3939590T3 (enExample)
ES (2) ES2967259T3 (enExample)
FI (1) FI3939590T3 (enExample)
HR (1) HRP20220317T1 (enExample)
HU (2) HUE065224T2 (enExample)
IL (1) IL258224B (enExample)
LT (1) LT3352752T (enExample)
PL (2) PL3939590T3 (enExample)
PT (2) PT3939590T (enExample)
RS (1) RS62988B1 (enExample)
SG (2) SG10202010598SA (enExample)
SI (1) SI3352752T1 (enExample)
SM (1) SMT202200167T1 (enExample)
UA (1) UA123865C2 (enExample)
WO (1) WO2017053373A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220142989A1 (en) * 2015-09-21 2022-05-12 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
UA123865C2 (uk) * 2015-09-21 2021-06-16 Люмос Фарма, Інк Визначення та лікування дефіциту гормону росту
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
AU2019325479B2 (en) 2018-08-20 2025-07-31 Bessor Pharma, Llc Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
WO2024096892A1 (en) 2022-11-03 2024-05-10 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000759A1 (en) * 1992-06-29 1994-01-06 University Of South Florida Diagnostic procedure for evaluating short stature etiology
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CN1213036C (zh) * 1997-08-22 2005-08-03 科研制药株式会社 新的酰胺类衍生物
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
US6861409B2 (en) 2000-06-13 2005-03-01 Zentaris Ag Growth hormone secretagogues
AR046778A1 (es) * 2003-11-12 2005-12-21 Phenomix Corp Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas.
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
UA123865C2 (uk) * 2015-09-21 2021-06-16 Люмос Фарма, Інк Визначення та лікування дефіциту гормону росту

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000759A1 (en) * 1992-06-29 1994-01-06 University Of South Florida Diagnostic procedure for evaluating short stature etiology
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E CODNER, ET AL., "Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth....", CLINICAL PHARMACOLOGY AND THERAPEUTICS,(2001), vol. 70, no. 1, pages 91 - 98 *

Also Published As

Publication number Publication date
WO2017053373A1 (en) 2017-03-30
AU2024201658A1 (en) 2024-04-04
US20190015394A1 (en) 2019-01-17
AU2025237934A1 (en) 2025-10-16
JP2021063096A (ja) 2021-04-22
JP7389862B2 (ja) 2023-11-30
US20180071266A1 (en) 2018-03-15
ES2967259T3 (es) 2024-04-29
CA2998523A1 (en) 2017-03-30
PT3939590T (pt) 2024-01-23
JP7724831B2 (ja) 2025-08-18
US10898472B2 (en) 2021-01-26
JP6816149B2 (ja) 2021-01-20
JP2022163012A (ja) 2022-10-25
EP4296679A2 (en) 2023-12-27
NZ741142A (en) 2025-05-02
IL258224A (en) 2018-05-31
EP3939590A1 (en) 2022-01-19
KR102385669B1 (ko) 2022-04-13
US9763919B2 (en) 2017-09-19
US20250213536A1 (en) 2025-07-03
JP2025170274A (ja) 2025-11-18
EP3939590B1 (en) 2023-11-29
EP3352752A1 (en) 2018-08-01
KR20180082428A (ko) 2018-07-18
LT3352752T (lt) 2022-04-11
PT3352752T (pt) 2022-03-09
KR20230116961A (ko) 2023-08-04
CN116459250A (zh) 2023-07-21
AU2021254600A1 (en) 2021-11-18
KR20250102122A (ko) 2025-07-04
US20170079961A1 (en) 2017-03-23
PL3352752T3 (pl) 2022-04-19
KR102560838B1 (ko) 2023-07-27
AU2016328969A1 (en) 2018-04-26
EP3352752B1 (en) 2021-12-22
DK3352752T3 (da) 2022-02-28
AU2021254600B2 (en) 2024-02-15
SMT202200167T1 (it) 2022-05-12
US10105352B2 (en) 2018-10-23
ES2908423T3 (es) 2022-04-29
HUE057831T2 (hu) 2022-06-28
SG10202010598SA (en) 2020-11-27
PL3939590T3 (pl) 2024-03-25
AU2024201658B2 (en) 2025-10-30
CN108348501A (zh) 2018-07-31
KR20220047407A (ko) 2022-04-15
CA2998523C (en) 2023-08-01
JP2024026112A (ja) 2024-02-28
HRP20220317T1 (hr) 2022-05-13
FI3939590T3 (fi) 2023-12-14
HK1263178A1 (zh) 2020-01-31
SG10201902424TA (en) 2019-04-29
JP2018529766A (ja) 2018-10-11
SI3352752T1 (sl) 2022-05-31
HUE065224T2 (hu) 2024-05-28
DK3939590T3 (da) 2023-12-18
CY1125183T1 (el) 2023-06-09
AU2020233715B2 (en) 2021-09-30
RS62988B1 (sr) 2022-03-31
EP3352752A4 (en) 2019-06-12
IL258224B (en) 2021-10-31
UA123865C2 (uk) 2021-06-16
JP7104768B2 (ja) 2022-07-21
AU2020233715A1 (en) 2020-10-22
EP4296679A3 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
AU2021254600B2 (en) Detecting and treating growth hormone deficiency
US11234969B2 (en) Detecting and treating growth hormone deficiency
US20220142989A1 (en) Detecting and treating growth hormone deficiency
HK40068057B (en) Detecting and treating growth hormone deficiency
HK40105706A (en) Detecting and treating growth hormone deficiency
HK40068057A (en) Detecting and treating growth hormone deficiency
HK1263178B (en) Detecting and treating growth hormone deficiency

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AMMONETT PHARMA LLC

Free format text: FORMER NAME(S): AMMONETT PHARM LLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LUMOS PHARMA, INC.

Free format text: FORMER OWNER(S): AMMONETT PHARMA LLC